Association of paraoxonase activity and coronary collateral flow

Coronary Artery Disease

Volumn 19, Issue 7, 2008, Pages 441-447

  Yildiz, Ali ^a   Sezen, Yusuf ^a   Gur, Mustafa ^a   Yilmaz, Remzi ^a   Demirbag, Recep ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Coronary collateral flow; Endothelial dysfunction; Nitric oxide; Oxidative stress; Paraoxonase

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; BIOCHEMICAL MARKER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, LDL; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY OCCLUSION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 55749092139     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328309b9f0     Document Type: Article

References (49)

1. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986; 74:469-476.
2. Pohl T, Seiler C, Billinger M, Herren E, Wustmann K, Mehta H, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol 2001; 38: 1872-1878.
3. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 2000; 190:338-342.
4. Abaci A, Oguzhan A, Kahraman S, Erol NK, Unal S, Arinc H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99:2239-2242.
5. Kilian JG, Keech A, Adams MR, Celermajer DS. Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 2002; 13:155-159.
6. Paurati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146:876-881.
7. Boodhwani M, Sodha NR, Mieno S, Xu SH, Feng J, Ramlawi B, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation 2007; 116(11 Suppl):131-137.
8. Harrison DG, Sellke FW, Quillen JE. Neurohumoral regulation of coronary collateral vasomotor tone. Basic Res Cardiol 1990; 85 (Suppl 1): 121-129.
9. Gulec S, Ozdemir AO, Maradit-Kremers H, Dincer I, Atmaca Y, Erol C. Elevated levels of C-reactive protein are associated with impaired coronary collateral development. Eur J Clin Invest 2006; 36:369-375.
10. Aras D, Geyik B, Topaloglu S, Ergun K, Ayaz S, Maden O, et al. Serum level of lipoprotein (a) is inversely associated with the development of coronary collateral circulation. Coron Artery Dis 2006; 17:159-163.
11. Guray U, Erbay AR, Guray Y, Yilmaz MB, Boyaci AA, Sasmaz H, et al. Poor coronary collateral circulation is associated with higher concentrations of soluble adhesion molecules in patients with single-vessel disease. Coron Artery Dis 2004; 15:413-417.
12. Seiler C, Pohl T, Billinger M, Meier B. Tumour necrosis factor alpha concentration and collateral flow in patients with coronary artery disease and normal systolic left ventricular function. Heart 2003; 89:96-97.
13. Demirbag R, Gur M, Yilmaz R, Kunt AS, Erel O, Andac MH. Influence of oxidative stress on the development of collateral circulation in total coronary occlusions. Int J Cardiol 2007; 116:14-19.
14. Watson AO, Berliner JA, Kama SY, U Du BN, Faull KF, Fogefcnan AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
15. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Ou BN. Paraoxonase inhibits high-density ltpoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
16. Graner M, James RW, Kahn J, Nieminen MS, Syvänne M. Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Colt Cardiol 2006; 47:2429-2435.
17. Gur M, Asian M, Yildiz A, Demirbag R, Yilmaz R, Selek S, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36:779-787.
18. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183:349-354.
19. Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuulila P, et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79:449-458.
20. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5: 587-592.
21. Eckerson HW, Wyle CM, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983; 35:1126-1138.
22. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3·1·1·2) based upon inhibition of enzymatic hydrolysis of 4-nrtrophenyl acetate by phenyl acetate. Bur J Clin Chem Clim Biochem 1992; 30: 391-395.
23. Billinger M, Kloos P, Eberti FR, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow up study in 403 patients with coronary artery disease. J Am Coll Cardiol 2002; 40:1545-1550.
24. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 1989; 117:290-295.
25. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Temn ML, et al. Influence of coronary collateral vessels on mvocardial infarct size in humans: results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI investigators. Circulation 1991; 83:739-746.
26. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Keamey M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99:111-120.
27. Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, et al. Hyperchotesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokmes. Circulation 1997; 96:2667-2674.
28. Kynakides ZS, Kremastinos DT, Michelakakis NA, Matsakas EP, Demovelis T, Toutouzas PK. Coronary collateral circulation in coronary artery disease and systemic hypertension. Am J Cardiol 1991; 67:687-690.
29. Lindner V, Maciag T. The putative convergent and divergent natures of angiogenesis and arteriogenesis. Circ Res 2001; 89:747-749.
30. Van Royen N, Piek JJ, Schaper W, Bode C, Buschmann I. Arteriogenesis: mechanisms and modulation of collateral artery development. J Nuclear Cardiol 2001; 8:687-693.
31. Rapps JA, Myers PR, Zhong Q, Parker JL Development of endothelium-dependent relaxation in canine coronary collateral arteries. Circulation 1998; 98:1675-1683.
32. Lavi S, McConnell JP, Lavi R, Bareness GW, Rihal CS, Novak GD, et al. Association between the paraoxonase-1 192Q>R allelic variant and coronary endothelial dysfunction in patients with early coronary artery disease. Mayo Clin Proc 2008; 83:158-164.
33. Yildiz A, Gur M, Yilmaz R Demirbag R, Polat M, Selek S, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008; 197:257-263.
34. Ito T, Yasue H, Yoshimura M, Nakamura S, Nakamura S, Nakayama M, et al. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 2002; 110:89-94.
35. Mashiba J, Koike G, Kamiunten H, Ikeda M, Sunagawa K. Vasospastic angina and microvascular angina are differentially influenced by PON1 A632G polymorphism in the Japanese. Circ J 2005; 69:1466-1471.
36. Paolisso G, Manzella D, Tagliamonte MR, Barbieri M, Marfella R. Zito G, et al. The BB paraoxonase genotype is associated with impaired brachial reactivity after acute hypertrigryceridemia in healthy subjects. J Clin Endocrinol Metab 2001; 86:1078-1082.
37. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34:774-784.
38. Lee CM, Chien CT, Chang PY, Hsieh MY, Jui HY, Liau CS, et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005; 183:251-258.
39. Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999; 19:1156-1161.
40. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139.
41. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101:2567-2578.
42. Unthank JL, Nixon JC, Dalsing MC. Nitric oxide maintains dilation of immature and mature collaterals in rat hindlimb. J Vasc Res 1996; 33:471-479.
43. Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996; 16:1256-1262.
44. Buckwalter JB, Curtýs VC, Valýc Z, Ruble SB, Clifford PS. Endogenous vascular remodeling in ischemic skeletal muscle: a role for nitric oxide. J Appl Physiol 2003; 94:935-940.
45. Matsunaga T, Wartlier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischaemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102: 3098-3103.
46. Gulec S, Karabulut H, Ozdemir AO, Ozdol C, Turhan S, Altin T, et al. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis 2008; 198:354-359.
47. White FC, Carroll SM, Magnet A, Bloor CM. Coronary collateral development in swine after coronary artery occlusion. Circ Res 1992; 71:1490-1500.
48. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-1457.
49. Kotur-Stevuljevic J, Spasic S, Stefanovic A, Zeljkovic A, Bogavac-Stanojevic N, Kalimanovska-Ostric D, et al. Paraoxonase-1 (PON1) activity, but not PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006; 44: 1206-1213.